Ubs Group Ag Pax Medica, Inc. Transaction History

Ubs Group Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.27 - $0.88 $296 - $966	1,098 New	1,098 $0
Q1 2023 May 12, 2023	SELL	$1.42 - $3.62 $22,249 - $56,721	-15,669 Reduced 46.91%	17,735 $33,000
Q4 2022 Feb 08, 2023	BUY	$1.4 - $53.55 $38,077 - $1.46 Million	27,198 Added 438.25%	33,404 $67,000
Q3 2022 Nov 10, 2022	BUY	$2.25 - $43.69 $13,963 - $271,140	6,206 New	6,206 $15,000

Ticker PXMD
Exchange
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,779,500
Market Cap $707K
Description
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, my...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.